One Pager as on September 30, 2024
Invests in segments with strongest contribution potential to India's growing GDP | |
Focuses on segments largely insulated from global volatility | |
Participating in India’s Consumption Growth Theme | |
Sector | MMCF* | Nifty India Consumption TRI |
Fast Moving Consumer Goods | 33.42% | 30.71% |
Consumer Services | 19.89% | 15.09% |
Automobile And Auto Components | 18.99% | 22.39% |
Consumer Durables | 9.46% | 10.11% |
Telecommunication | 5.48% | 9.75% |
*Mahindra Manulife Consumption Fund
Data as on September 30, 2024
Security | % to Net Assets |
Hindustan Unilever Limited | 6.92% |
Mahindra & Mahindra Limited | 6.25% |
ITC Limited | 5.51% |
Zomato Limited | 3.68% |
Bharti Airtel Limited | 3.68% |
Trent Limited | 3.62% |
Maruti Suzuki India Limited | 3.16% |
Hero MotoCorp Limited | 3.11% |
Havells India Limited | 2.67% |
Asian Paints Limited | 2.56% |
Total Total | 41.17% |
Turnover Ratio (Last 1 year) | 0.62 |
Standard Deviation | 11.89% |
Beta | 0.80 |
Sharpe Ratio# | 1.23 |
Jenson's Alpha | 0.2240 |
#Risk-free rate assumed to be 6.76% (MIBOR as on 30-09-24) - Source:www.mmda.org
Note: As per AMFI guidelines for factsheet, the ratios are calculated based on month rolling returns for last
3 years. Data as on September 30, 2024
Fresh Additions | Complete Exits |
Security | Security |
Balrampur Chini Mills Limited | Glenmark Pharmaceuticals Limited |
Devyani International Limited | Varroc Engineering Limited |
Emami Limited | - |
Note: The companies/stock(s) referred above are only for the purpose of disclosure of significant portfolio
changes during the month and should not be construed as recommendation to buy/sell/ hold. The fund
manager may or may not choose to hold these companies/stocks, from time to time. Investors are
requested to consult their financial, tax and other advisors before taking any investment decision(s). Data
as on September 30, 2024
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 13-Nov-18.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Abhinav Khandelwal is managing this scheme since April 1, 2022. Ms. Fatema Pacha is managing this scheme since December 21, 2020. *Based on standard investment of Rs. 10,000 made at the beginning of the relevant period.
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 13-Nov-2018.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business day of
every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
The performance details provided above are of
Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Abhinav Khandelwal manages 6 schemes and
Ms. Fatema Pacha manages 8 schemes of Mahindra Manulife Mutual Fund. The performance data for the schemes which have not completed one year has not been provided.
Performance as on September 30, 2024
This product is suitable for investors who are seeking*:
• Long term capital appreciation;
• Investment predominantly in
equity and equity related securities
including derivatives of entities
engaged in and/ or expected to
benefit from the consumption led
demand in India.
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.